Key Figures

UNH stock is up more than 20% year-to-date and 39% over the past six months. The medical care ratio improved to 85.3% from 87.1% a year earlier, with medical costs down 2% to $148.8 billion. The 2026 EPS estimate stands at $19.82, reflecting 21% year-over-year growth. Wall Street holds a Strong Buy consensus with an average price target of $481.67, implying 21% upside. UnitedHealthcare is cutting 30% of remaining prior authorization requirements.

UNH stock currently trades around $397, up more than 20% year-to-date and roughly 39% over the past six months. That run has outpaced the S&P 500's 12% gain over the same stretch.

The recovery is being driven by easing medical cost pressures. In the first half of 2026, UnitedHealth's medical care ratio dropped to 85.3% from 87.1% a year earlier, while total medical costs fell 2% to $148.8 billion. The medical care ratio — the share of premium dollars spent on medical claims — is the most closely watched profitability gauge for health insurers, so even a modest improvement tends to move the stock meaningfully.

The company has also been pulling back from lower-return businesses. UNH is exiting certain Medicare Advantage and Optum Health markets to cut losses and redirect capital toward more profitable areas. This kind of pruning is a common playbook among managed-care insurers when Medicare Advantage plans become unprofitable: withdrawing from counties where reimbursement does not cover costs, then re-entering once pricing resets.

Capital returns have added to investor confidence. Through mid-July 2026, UNH had repurchased $4 billion of stock and remains on track to buy back at least $5 billion for the full year. It also paid $4.1 billion in dividends in the first half.

Prior Authorization Changes

UnitedHealthcare announced it is removing 30% of its remaining prior authorization requirements, covering surgeries, diagnostic tests, and therapies. The move is expected to reduce administrative friction and improve member satisfaction. It also follows years of pressure from regulators, physicians, and patient groups over prior authorization delays, which culminated in CMS rules requiring faster insurer responses to coverage requests.

The trade-off is real, though. Fewer checks could push up healthcare utilization and lift medical costs. Management will need its pricing and care management approach to absorb any increases. How that balance plays out will be visible in the medical care ratio over the coming quarters — the single metric most likely to confirm or challenge the recovery narrative.

Earnings Outlook

The Zacks consensus estimate for 2026 EPS is $19.82, up 21.2% year-over-year. That estimate has received two upward revisions in the past month with no downward moves.

For 2027, EPS is projected to grow another 13.7% to $22.54, with revenue rising 2.6% to $458.33 billion. The gap between low single-digit revenue growth and double-digit EPS growth reflects the margin-repair story — earnings recovery driven by cost discipline and business exits rather than top-line expansion, which is precisely the concern cited by the more cautious analysts. UNH has beaten earnings estimates in each of the past four quarters, with an average surprise of 12.1%.

On valuation, UNH trades at 18.51x forward earnings, above the industry average of 16.13x but still below its own five-year median of 19.11x.

Bernstein analyst Lance Wilkes reiterated a Buy rating last week with a $512 price target. He highlighted Optum Insight as a key long-term growth driver, particularly for AI-powered healthcare operations.

Not everyone is fully on board. Erste Group analyst Hans Engel recently downgraded UNH to Hold, citing revenue growth in 2026 and 2027 that he sees as low relative to sector peers, combined with a stretched valuation multiple.

Wall Street overall carries a Strong Buy consensus on UNH, with 16 Buy ratings and five Holds. The average price target of $481.67 implies about 21% upside from current levels.

The April CMS decision to raise 2027 Medicare Advantage payments by an average of 2.48%, well above the initially proposed 0.09%, also gave the reimbursement picture a boost. Because Medicare Advantage is one of UnitedHealthcare's largest lines of business, government rate setting is a recurring swing factor for the stock — final CMS payment rules each spring routinely move managed-care shares.

For investors tracking whether the rally has further to run, the items to watch are straightforward: whether the medical care ratio holds near current levels as prior authorization requirements roll off, whether Medicare Advantage margins continue to recover under the higher 2027 rates, and whether Optum's data and AI-driven businesses sustain the growth Bernstein and other bulls are counting on.

Source: CoinCentral